Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
The higher response rate depends on four MRD-negative patients who have not yet reached complete response.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immix Biopharma (IMMX) reported an 89% complete response rate across all 45 patients in its interim NEXICART-2 trial update.
An independent review committee found complete responses in 40 of 45 patients treated with NXC-201 in the Phase 2 study of relapsed or refractory AL amyloidosis. Among 25 newly reported patients, 21 reached complete response and the remaining four were negative for minimum residual disease (MRD), a bone-marrow measure. Those four have not yet reached complete response; Immix says their MRD-negative results could lift the eventual rate to as much as 98% (44 of 45). No relapses have been observed among patients reaching complete response or MRD-negativity, and no neurotoxicity or enterocolitis has been observed to date.
Immix plans the final NEXICART-2 readout and a biologics license application (BLA) submission for mid-2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point40 of 45 patients achieved complete response, an 89% rate assessed by independent review.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Final readout and BLA submission are planned for mid-2027.
- Minor point21 of 25 newly reported patients achieved complete response; the other four were MRD-negative.
- Minor point. Forward-looking: it has not happened yet and may not happen.98% (44 of 45) is the potential complete response rate if the four pending patients respond.
- Minor pointNo relapses have been observed to date among patients reaching complete response or MRD-negativity.
- Minor pointNo neurotoxicity or enterocolitis has been observed to date.
Negative
- Minor pointFour MRD-negative patients have not yet achieved complete response.
- Minor point. Forward-looking: it has not happened yet and may not happen.Interim results precede the final NEXICART-2 readout planned for mid-2027.
News Explained
Immix says all patients reaching MRD-negativity to date reached complete response within one year of treatment, providing a historical time frame for the four MRD-negative cases still pending—not confirmation that they have reached complete response.
Details
Market Reaction – IMMX
On Sep 29, the day this news came out, the latest delayed price for IMMX is 1.57% above the previous close. Argus tracked a peak move of +5.0% during the session. Argus tracked a trough of -18.9% from its starting point during tracking. Our momentum scanner has recorded 16 alerts for this stock so far that day. The latest delayed price is $11.65. Relative volume is exceptionally heavy at 295.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- New patients in CR or MRD-negative
- 100% (25/25)
- NEXICART-2 interim update
- Complete response rate
- 89% (40/45)
- Across all NEXICART-2 patients; independent review committee assessment
- Potential complete response rate
- Up to 98% (44/45)
- Potential future rate based on four pending patients already MRD-negative
- Planned final readout and BLA submission
- Mid-2027
- NEXICART-2
Historical Context
-
NEXICART-2 interim update reported 95% CR among 20 patients, with no relapses among CR patients.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
complete response medical
minimum residual disease medical
car-t medical
bcma-targeted medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
–
– To-date, all patients achieving MRD-negativity reached CR within one year of treatment –
– Across all forty-five patients, NXC-201 produced an
– In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to
– No relapses observed for any patient who reached CR or MRD-negativity to-date –
– No neurotoxicity or enterocolitis has been observed to-date –
– NEXICART-2 final readout and BLA submission planned mid-2027 –
– Virtual investor event today Sep 29 at 8:00am ET: https://events.q4inc.com/attendee/484851283/ –
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced positive results of an
“Today, patients with AL Amyloidosis face years of burdensome, continuous treatment. As a potential one-and-done treatment option, NXC-201 could liberate patients from that burden,” said Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma, adding: “We are thrilled with NXC-201’s magnitude of effect across a broad range of relapsed/refractory AL Amyloidosis patients in NEXICART-2.” Gabriel Morris, President of Immix Biopharma, added, “NXC-201’s complete response rate continues to increase over time, even as reported patient counts have now more than doubled. We look forward to final readout, BLA submission and potentially making NXC-201 available to relapsed/refractory AL Amyloidosis patients at commercial launch.”
Investor Webcast and Conference Call Information
The Company will host a conference call to discuss these data at 8:00 a.m. ET today, Sep 29, 2026. The live webcast can be accessed at https://events.q4inc.com/attendee/484851283/ or under “Events & Presentations” in the Investors section of the company’s website at www.immixbio.com. The webcast will be available for replay on the company website. Analysts who wish to join the teleconference and participate in Q&A should register at the link above.
About NEXICART-2
NEXICART-2 (NCT06097832) is a multi-site U.S. Phase 2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. NEXICART-2 is a 45-patient study.
About AL Amyloidosis
AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death.
The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at
The Amyloidosis market was
About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, statements relating to NEXICART-2 final readout and BLA submission planned in mid-2027; making NXC-201 available to patients at commercial launch, if approved; the size of the AL Amyloidosis market; the potential benefits of our product candidate NXC-201 and the timing and results related to clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the estimates for the number of patients in the U.S. with relapsed/refractory AL Amyloidosis and the market size reaching not being accurate; (ii) the risk that Breakthrough Therapy designation will not expedite the development of NXC-201: (iii) the risk that further data from the ongoing Phase 1/2 clinical trials for NXC-201 will not be favorably consistent with the data readouts to date, (iv) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (v) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (vi) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (vii) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (viii) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (ix) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2026 and other periodic or current reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was Immix Biopharma’s complete response rate in the NEXICART-2 interim update?
The independently assessed complete response rate was 89% (40 of 45 patients) across the NEXICART-2 study.